Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity.

Journal of medicinal chemistry·2026
Same author

Research Progress and Clinical Translation Challenges of Small-Molecule Inhibitors Targeting PD-L1.

ChemMedChem·2026
Same author

Antineuroblastoma Activity Evaluation and Mechanism of Novel PD-L1 Small Molecule Inhibitors through Immune and Non-Immune Pathways.

ACS pharmacology & translational science·2025
Same author

Progress in the Research and Development of Biphenyl Small Molecules Targeting PD-1/PD-L1 as Potential Antitumor Drug Candidates.

ChemMedChem·2025
Same author

Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2'-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors.

Journal of medicinal chemistry·2023
Same author

Exploring potential bacterial populations for enhanced anthraquinone dyes biodegradation: a critical review.

Biotechnology letters·2022

相关实验视频

Updated: Jan 6, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.0K

小分子抑制剂针对结直肠癌中的PD-1/PD-L1:机制,挑战和临床前景

Jianwei Wang1,2, Shenwei Yu1,2,3, Liang Qian2,3

  • 1Lab of Drug Design and Synthesis, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China.

ChemMedChem
|November 23, 2025
PubMed
概括

针对PD-1/PD-L1的小分子抑制剂为结直肠癌 (CRC) 治疗提供了新的希望,特别是对于微卫星稳定 (MSS) 瘤. 这些药物在克服免疫逃避和增强CRC免疫疗法疗效方面表现有前途.

关键词:
在PD-1/PD-L1轴上结肠直肠癌是什么意思免疫检查点抑制剂 免疫检查点抑制剂小分子抑制剂 小分子抑制剂瘤微环境是一个微环境.

更多相关视频

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K
Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
08:42

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

1.8K

相关实验视频

Last Updated: Jan 6, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.0K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K
Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
08:42

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

1.8K

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 结肠直肠癌 (CRC) 是一个重大的全球健康挑战,其特点是遗传改变和免疫抑制瘤微环境 (TME).
  • PD-1/PD-L1免疫检查点对于CRC免疫规避至关重要,代表了一个关键的治疗标.
  • 虽然免疫检查点抑制剂 (ICI) 有利于MSI-H/dMMR CRC,但由于免疫逃生机制,MSS CRC显示出有限的反应.

研究的目的:

  • 审查PD-1/PD-L1轴在结直肠癌中的作用.
  • 讨论针对CRC中PD-1/PD-L1的小分子抑制剂的治疗潜力.
  • 探索这些抑制剂作为下一代CRC免疫疗法的未来前景.

主要方法:

  • 文献综述总结了CRC中PD-1/PD-L1轴的当前研究.
  • 针对PD-1/PD-L1的小分子抑制剂及其作用机制的分析.
  • 对固体瘤中小分子PD-1/PD-L1抑制剂的早期临床试验数据的评估,包括CRC.

主要成果:

  • 小分子抑制剂比单克隆抗体具有优势,包括口服和更好的组织透.
  • 一些化合物 (例如MPT0G612,Panaxadiol,Butyrate) 通过调节PD-L1表达或T细胞透来表现出抗瘤作用.
  • 早期对CA-170,INCB086550和ASC61等药物的临床试验显示,在包括CRC在内的固体瘤中具有有前途的活性.

结论:

  • 针对PD-1/PD-L1的小分子抑制剂代表了结直肠癌的有希望的治疗策略,特别是在MSS瘤中.
  • 这些抑制剂可以克服免疫逃生机制,并提高癌症免疫治疗的疗效.
  • 小分子PD-1/PD-L1抑制剂的进一步临床开发具有促进CRC治疗的巨大潜力.